Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 202Carcinoma, Renal Cell 68Liver Neoplasms 61Neoplasms 53Neoplasm Metastasis 34Leukemia, Myeloid, Acute 34Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 29Melanoma 24Kidney Neoplasms 21Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Recurrence 13Glioblastoma 13Thyroid Neoplasms 11Colorectal Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Carcinoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

infigratinib 1Sorafenib 1Diet, Sodium-Restricted 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypophosphatemia × Sorafenib × Clear all
NCT00622479 2014-12-18

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Bayer

Phase 1 Terminated
12 enrolled
Genitourinary

Carcinoma, Renal Cell, Hypophosphatemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡